Back to top

Wedbush sees no threat to Ascendis’ Yorvipath from competitor data

Wedbush analyst Yun Zhong does not believe the Phase 2 top-line data that MBX Biosciences (MBX) announced from a Phase 2 study in hypoparathyroidis...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Ascendis Pharma A/S (ASND)

MBX Biosciences, Inc. (MBX)